5α-reductase activity and prostate cancer: A case-control study using stored sera

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 1, 1997, Pages 21-24

  Guess, Harry A ^a,b   Friedman, Gary D ^c   Sadler, Marianne C ^c   Stanczyk, Frank Z ^d   Vogelnian, Joseph H ^e   Imperato McGinley, Julianne ^f   Lobo, Rogerio A ^g   Orentreich, Norman ^e  

^a IL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Orentreich Foundation   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; STEROID 5ALPHA REDUCTASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SEROEPIDEMIOLOGY; SMOKING; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANDROSTERONE; CASE-CONTROL STUDIES; CHOLESTENONE 5 ALPHA-REDUCTASE; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031025116     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Nomura, A. M. Y., and Kolonel, L. N. Prostate cancer: a current perspective. Epidemiol. Rev.,13: 200-227, 1991.
2. Wilson, J. D. The pathogenesis of benian prostatic hyperplasia. Am. J. Med.,68: 745-756, 1980.
3. Wilson, J. D. The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog. Horm. Res.,26: 309-336, 1990.
4. Wilbert, D. M., Griffin, J. E., and Wilson, J. D. Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocr. Metab.,56: 113-120, 1983.
5. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
6. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Binkowitz, B., and Ng, J. for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med.,327: 1185-1191, 1992.
7. Fair, W. R., Presti, J. C., Sogani, P., Andriole, G., Seidmon, E. J., Ferguson, D., and Gormley, G. J. Multi-center, randomized, double-blind, placebo-controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer (Abstract 419). 1991 American Urologie Association Annual Meeting, Toronto, Ontario, Canada, 1991.
8. Feigl, P., Blumenstein, B., Thompson, I., Crowley, J., Wolf, M., Kramer, B. S., Coltman, C. A., Jr., Brawley, O. W., and Ford, L. G. Design of the prostate cancer prevention trial (PCPT). Controlled Clin. Trials, 16: 150-163, 1995.